Highlights
- •Moxifloxacin daily doses of 2400 mg were tolerated over several months.
- •M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.
- •No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.
- •No eradication of M. tuberculosis despite longstanding culture conversion.
- •Development of pretomanid resistance on an insufficient treatment regimen.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Proteomic analysis of sequential isolates of multidrug-resistant Mycobacterium tuberculosis during treatment failure.J Infect. 2022; 85: e137-e139
World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022.
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. 2022 update ed. Geneva: World Health Organization; 2022.
- A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.J Chromatogr B. 2022; 1211123456
- A sensitive and high-throughput quantitative liquid chromatography high-resolution mass spectrometry method for therapeutic drug monitoring of 10 beta-lactam antibiotics, linezolid and two beta-lactamase inhibitors in human plasma.Biomed Chromatogr. 2021; e5092
- Population pharmacokinetics and bayesian dose adjustment to advance TDM of anti-TB drugs.Clin Pharmacokinet. 2021; 60: 685-710
- Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.J Antimicrob Chemother. 2021; 76: 1019-1024
- Novel 6-month treatment for drug-resistant tuberculosis, United States.Emerg Infect Dis. 2021; 27
- Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.Antimicrob Agents Chemother. 2015; 59: 673-676
- Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis.Antimicrob Agents Chemother. 2004; 48: 2228-2232
Article info
Publication history
Published online: February 02, 2023
Accepted:
January 30,
2023
Identification
Copyright
© 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
